Biotech Breakouts and Takeover Targets

May 13, 2016

From Bloodbath to Bio-Boom

Biotechs have suffered something of a bloodbath recently.

On the whole, biotech stocks are down 25% so far this year. That’s how much the iShares NASDAQ Biotech Index (NASDAQ: IBB) is down, anyway. The SPDR S&P Biotech ETF (NYSE: XBI), is faring even worse, down about 30%.

Year-to-date, Biogen (NASDAQ: BIIB) is down 14%, Celgene Corp. (NASDAQ: CELG) is down 16%, Gilead Sciences (NASDAQ: GILD) is down 18.5%, and BioMarin Pharm (NASDAQ: BMRN) is down roughly 24%.

This might be concerning… if biotech stocks had not just completed the greatest bull run in the history of the industry.

Continue Reading at OutsiderClub.com…

Financial Survival Network (FSN) content is informational only and based on information available at the time of creation. It is not an offer or solicitation, nor does it provide investment, tax, or legal advice. It may not consider your specific financial circumstances or objectives and may not be suitable for you. FSN content is not a recommendation to buy or sell any securities. Readers should consult their own professional advisers and conduct their own independent investigations before making any investment decisions. FSN does not guarantee the accuracy or completeness of its content or any third-party information it uses, which has not been independently verified by FSN. Readers are cautioned not to rely solely on FSN content for investment decisions.

FSN and its owner may have financial interests in the companies discussed and may trade such securities without prior notice. FSN is funded by sponsor advertisements, with payments ranging from five to ten thousand dollars monthly. FSN does not charge its viewers/listeners/readers any fees. By accessing FSN content, users agree that FSN and its affiliates are not liable for any inaccuracies, omissions, or representations in the content provided.